4CMenB vaccine effectiveness: reasons for optimism
- PMID: 28100431
- PMCID: PMC5424821
- DOI: 10.1016/S0140-6736(16)32061-X
4CMenB vaccine effectiveness: reasons for optimism
Comment on
-
Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.Lancet. 2016 Dec 3;388(10061):2775-2782. doi: 10.1016/S0140-6736(16)31921-3. Epub 2016 Oct 27. Lancet. 2016. PMID: 28100432
References
-
- Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–63. - PubMed
-
- Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9:285–98. - PubMed
-
- Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(Suppl 2):B20–9. - PubMed
-
- Esposito S, Principi N. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine. Expert Rev Vaccines. 2014;13:193–202. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
